336 related articles for article (PubMed ID: 31385933)
1. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
3. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
5. A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
Vo AA; Choi J; Kim I; Louie S; Cisneros K; Kahwaji J; Toyoda M; Ge S; Haas M; Puliyanda D; Reinsmoen N; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Nov; 99(11):2356-63. PubMed ID: 26018350
[TBL] [Abstract][Full Text] [Related]
6. Donor-Specific Antibodies in Kidney Transplant Recipients.
Zhang R
Clin J Am Soc Nephrol; 2018 Jan; 13(1):182-192. PubMed ID: 28446536
[TBL] [Abstract][Full Text] [Related]
7. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection.
Doberer K; Kläger J; Gualdoni GA; Mayer KA; Eskandary F; Farkash EA; Agis H; Reiter T; Reindl-Schwaighofer R; Wahrmann M; Cohen G; Haslacher H; Bond G; Simonitsch-Klupp I; Halloran PF; Böhmig GA
Transplantation; 2021 Feb; 105(2):451-457. PubMed ID: 32235256
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
[TBL] [Abstract][Full Text] [Related]
9. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.
Lavacca A; Presta R; Gai C; Mella A; Gallo E; Camussi G; Abbasciano I; Barreca A; Caorsi C; Fop F; Messina M; Rossetti M; Biancone L
Clin Transplant; 2020 Aug; 34(8):e13908. PubMed ID: 32415711
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP
Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
12. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
Front Immunol; 2022; 13():839380. PubMed ID: 35493469
[TBL] [Abstract][Full Text] [Related]
15. Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.
Shiu KY; McLaughlin L; Rebollo-Mesa I; Zhao J; Burton H; Douthwaite H; Wilkinson H; Semik V; Dodd PC; Brookes P; Lechler RI; Hernandez-Fuentes MP; Kemper C; Dorling A
Kidney Int; 2017 Feb; 91(2):477-492. PubMed ID: 27988211
[TBL] [Abstract][Full Text] [Related]
16. Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure.
Khovanova N; Daga S; Shaikhina T; Krishnan N; Jones J; Zehnder D; Mitchell D; Higgins R; Briggs D; Lowe D
Transpl Int; 2015 Dec; 28(12):1405-15. PubMed ID: 26264744
[TBL] [Abstract][Full Text] [Related]
17. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
18. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
19. Hidden perils in a highly sensitized kidney transplant recipient.
Ford S; Summers S; Cantwell L; Mulley W
Nephrology (Carlton); 2012 Apr; 17 Suppl 1():9-11. PubMed ID: 22497647
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
